ANGIOPROTECTIVE THERAPY IN PATIENTS WITH CHRONIC OBSTRUCTIVE PULMONARY DISEASE AND HYPERTENSIVE DISEASE

Download full text PDF
Issue: 
7
Year: 
2016

O. Titova (1), MD; N. Kuzubova (1), MD; Professor V. Volchkov (2), MD; E. Privalova (1), Can-didate of Medical Sciences; A. Shumilov (1); A. Gichkin (1), Candidate of Medical Sciences 1 -Research Institute of Pulmonology, Acad. I.P. Pavlov First Saint Petersburg State Medi-cal University 2 -Saint Petersburg State University

Sulodexide was tested for its effects on clinical and functional indicators in patients with chronic obstructive pulmonary disease (COPD) concurrent with hypertensive disease. One-year follow-up showed that patients who had additionally taken sulodexide had stabilization of blood pressure, reductions in dizziness and headache, an increase in exercise tolerance, a decline in the number of exacerbations, improvements in spirometry readings, diffusing lung capacity, and pulmonary hemodynamic parameters, and optimization of endotheliumdependent vasodilation, which lends support to the appropriateness of further investigation of angioprotectors used in the combination pathogenetic therapy of COPD.
Keywords: 
pulmonology
cardiology
chronic obstructive pulmonary disease
hypertension
endothelial function
cardiopulmonary hemodynamics
sulodexide

It appears your Web browser is not configured to display PDF files. Download adobe Acrobat или click here to download the PDF file.

References: 
  1. Chuchalin A.G. (red.) Pul'monologija / M.: GEOTAR-Media, 2014; 302 s.
  2. Karoli N.A., Rebrov A.P. Nekotorye mehanizmy razvitija legochnoj gipertenzii u bol'nyh hronicheskimi obstruktivnymi zabolevanijami leg-kih. Obzor literatury // Ter. arh. – 2005; 3: 87–93.
  3. Chuchalin A.G., Ajsanov Z.R., Avdeev S.N. i dr. Federal'nye klinicheskie rekomendatsii po diagnostike i lecheniju hronicheskoj obstruktivnoj bolezni legkih // Rus. med. zhurn. – 2014; 5: 331–48.
  4. Chuchalin A.G. (red.) Respiratornaja meditsina. T. I / M.: GEOTAR-Media, 2007; 787 s.
  5. WHO Key Facts COPD http://www.who.int/mediacentre/factsheets/fs315/en/ index.html
  6. Crisafulli E., Costi S., Luppi F. et al. Role of comorbidities in a cohort of patients with COPD undergoing pulmonary rehabilitation // Thorax. – 2008; 63: 487–92.
  7. Zadionchenko V.S., Adasheva T.V., Fedorova I.V. i dr. Arterial'naja gipertonija i hronicheskaja obstruktivnaja bolezn' legkih – kliniko-patogeneticheskie paralleli i vozmozhnosti terapii // Ros. kardiol. zhurn. – 2009; 6: 62–9.
  8. Zadionchenko V.S., Adasheva T.V., Li V.V. i dr. Arterial'naja giperten zija i hronicheskaja obstruktivnaja bolezn' legkih – problemy vybora terapii // Lechaschij vrach. – 2012; 7: 77–82.
  9. http://www.alfawassermann.ru
  10. Funktsional'naja diagnostika v pul'monologii. Pod red. A.G. Chuchalina 10. / M.: Atmosfera, 2009; 179 s.
  11. Kuznetsova V.K., Aganezova E.S, Jakovleva N.G. i dr. Metodika provede nija i unifitsirovannaja otsenka rezul'tatov funktsional'nogo issledova-nija mehanicheskih svojstv apparata ventiljatsii na osnove spirometrii. Posobie dlja vrachej / SPb: NII pul'monologii SPbGMU im. akad. I.P. Pavlova, 1996; 40 s.
  12. Celermajer D., Sorensen K., Gooch V. et al. Non-invasive detection of endothelial dysfunction children and adults at risk of atherosclerosis // Lancet. – 1992; 340 (8828): 1111–5.
  13. Corretti M., Anderson T., Benjamin E. et al. Guidelines for the ultrasound assessment of endothelial-dependent flow-mediated vasodilation of the brachial artery // J. Am. Coll. Cardiol. – 2002; 39: 257–65.
  14. Petrischev N.N., Vlasov T.D. Fiziologija i patofiziologija endotelija. V sb.: N.N. Petrischev (red.). Disfunktsija endotelija. Prichiny, mehanizmy, farmakologicheskaja korrektsija / SPb: 2003; s. 4–38.
  15. Petrischev N.N., Vlasov T.D., Kapitonova O.A. Endotelial'naja dis funktsija i metody ee korrektsii. V kn.: Materialy assamblei «Vrach-Provizor-Patsient». SPb: 2003; 100–57.
  16. Coccheri S. Biological and clinical effectes of sulodexide in arterias disorders and diseases // Int. Angiol. – 2014; 33 (3): 263–74
  17. Andreozzi G. Role of sulodexide in the treatment of CVD // Int. Angiol. – 17. 2014; 33 (3): 255–62.
  18. Coccheri S., Mannello F. Development and use of sulodexide in vascular 18. diseases: implications for treatment // Drug Des. Devel. Ther. – 2013; 8: 49–65.
  19. Lauver D., Booth E., White A. et al. Sulodexide attenuates myocardial 19. ischemia/reperfusion injury and the deposition of C-reactive protein in areas of infarction without affecting hemostasis // J. Pharmacol. Exp. Ther. – 2005; 312 (2): 794–800.
  20. Kuzubova N.A., Fedin A.N., Lebedeva E.S. i dr. Vlijanie endoteliopro-20. tektorov na tonus legochnyh arterij i bronhov na modeli obstruktivnoj patologii legkih // Ros. fiziol. zhurn. – 2014; 3: 339–47.
  21. Masola V. et al. Glycosaminoglycans, proteoglycans and sulodexide and 21. endothelium: biological roles and pharmacological effects // Int. Angiol. – 2014; 33 (3): 243–54.